Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus

Inclusion Criteria: * Adults aged 18-80 years old. * Have at least one active DLE lesion, either diagnosed by skin biopsy or confirmation by Dermatologist/ Rheumatologist. * Patients with DLE only and SLE patients with DLE are included. * Have refractory disease to an anti-malarial for at least 3 months as assessed by Dermatologist/Rheumatologist. * Patients receiving anti-malarials must have been receiving them for at least 3 months prior to Screening, with a stable dose regimen for at least 28 days (±1 day) prior to Baseline (the first study drug administration) * Ability to provide an informed consent. * All male and female patients biologically capable of having children must agree to use a reliable method of contraception for the duration of the study and for a period of 3 weeks after their final dose of study drug. Acceptable methods of contraception are surgical sterilisation, oral, implantable or injectable hormonal methods, intrauterine devices or barrier contraceptives. Exclusion Criteria: * Any prior treatment with TNF-blockade therapies. * Intramuscular or intra-dermal corticosteroid within 28 days of the Screening visit. * Corticosteroid of greater than 10mg prednisolone daily equivalent, or change in oral steroid dose within 28 days prior to Baseline Visit. * A change in the dose of other immunosuppressant including methotrexate, azathioprine and mycophenolate mofetil within 28 days (±1 day) prior to Baseline Visit. * Concomitant therapies with any alkylating…